Companies / Germany

Stada Rules Out Takeover

April 2006 | Company Finance Alert

Printable version
Bookmark

German generic firm Stada intends to resist a takeover, remain independent and seek acquisitions, according to a statement made by CEO Hartmut Retzlaff at the company's annual financial results

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Dr Reddy's Sales Impacted By AOK Tenders

Industry / Germany BMI View: Germany is keen to promote the use of generic drugs as it battles soaring drug spending. Therefore, while the sales of innovative drugs may experience a decline in Germany as a result of the...

January 2011

High Per-Capita Spending Creates Opportunities For Drugmakers

Industry / Germany BMI View: Despite the threat of austerity measures, the government's focus on cost containment within the pharmaceuticals and healthcare sector and the impact of generic competition as a result of the...

January 2011

Attractive To Innovative And Generic Drugmakers

Industry / Germany BMI View: Despite the threat of austerity measures and the government's focus on cost containment within the pharmaceuticals and healthcare sector, and the impact of generic competition as a result of...

January 2011

Emerging Markets Account For Increasing Percentage Of Merck KGaA Sales

Industry / Germany Germany-based drugmaker Merck KGaA has posted Q210 revenues of US$2.89bn, a 5.20% increase on Q110 revenues (US$2.74bn) and 16.10% increase on revenues of US$2.49bn in Q209. Merck's Q210 operating profit...

August 2010

Bayer Q210 Financial Results Reflects Increasing Reliance On Emerging Markets

Industry / Germany BMI Core View: Emerging markets will drive industry growth. The importance of emerging markets to large multinational drugmakers cannot be overstated and BMI's Pharmaceutical Expenditure Model reveals...

July 2010